ND
What it found
A paper reports the results; we have not read it yet. See Papers below.
What was tested
Treatment tested
- Amantadine
- Dalfampridine
Voltage-gated potassium channel blocker
What it measured
Main measures
evaluate the effects on brain activation patterns of drugs that are widely used in clinical practice for the treatment of fatigue in multiple sclerosis
Fatigue
Who could take part
MS (type not specified)
Inclusion: -No relapses and steroid treatment in the three months preceding study initiation; Exclusion: -Recurrence-and steroid treatment in the three months preceding the start of the study;
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
evaluate the effects on brain activation patterns of drugs that are widely used in clinical practice for the treatment of fatigue in multiple sclerosis
Papers
Results
Functional connectivity modifications in monoaminergic circuits occur in fatigued MS patients treated with fampridine and amantadine.J Neurol · 2023
At w4, fatigue scores decreased in all groups (p = range < 0.001-0.002).
Read by software from the paper's abstract
Loading reviews and guidelines…
Related trials
- AmpPT
Phase 3 · Recruiting
Still running
- SOLARIMS
Phase 2 · Recruiting
Still running
- FETEM
Phase 3 · Status unknown
Result in a paper, not read yet
- RESTORE
Phase 3 · Stopped early
Stopped: not working
- New strategies in neurological diseases
Phase 4 · Ongoing
Still running
- MUST
Not a drug-phase study · Completed
Result in a paper, not read yet
History
Started
Feb 2011
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error